Welcome to our dedicated page for Ping An Biomedical SEC filings (Ticker: PASW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Ping An Biomedical Co., Ltd. (NASDAQ: PASW) provides access to the company’s U.S. regulatory disclosures as they become available through the EDGAR system. Ping An Biomedical describes itself as a one-stop SCM service provider in the apparel industry and also as a company focused on healthcare and biomedical technology, and its filings are the primary source for detailed information on these activities.
Through this page, investors can review key filing types when they are submitted, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss business segments, risk factors, and management’s analysis of operations. Current reports on Form 8-K, when filed, can disclose material events such as strategic investment memoranda, share purchase agreements, or notices related to listing standards.
Ping An Biomedical has publicly reported receiving a Nasdaq minimum bid price deficiency letter, and any related developments may also appear in its SEC filings. In addition, ownership and insider activity, when reported on Form 3, 4, or 5, can be accessed from this page to understand changes in shareholdings of directors, officers, or significant holders.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents in plain language. Real-time updates from EDGAR, combined with AI-generated highlights of sections such as business descriptions, risk discussions, and capital market disclosures, help readers navigate Ping An Biomedical’s regulatory record more efficiently.
Ping An Biomedical Co., Ltd. entered into securities purchase agreements with accredited investors for a private placement of 100,000,000 ordinary shares at
The shares are being sold in an unregistered offering relying on Section 4(a)(2), Regulation D, and Regulation S exemptions. Investors must be accredited or non‑U.S. persons, and the ordinary shares will carry transfer restrictions and restrictive legends because they are not registered under the U.S. Securities Act.
Ping An Biomedical Co., Ltd. files its annual report on Form 20-F for the year ended September 30, 2025, covering its apparel-focused operations in China conducted through PRC subsidiary New Brand. As of September 30, 2025, 20,500,000 ordinary shares were outstanding.
The company highlights extensive risks tied to operating in mainland China and Hong Kong, including rapid regulatory changes, data and cybersecurity oversight, capital controls, and potential trading prohibitions under the HFCA Act if PCAOB access to auditors is restricted. It notes reliance on PRC and CSRC approvals for overseas listings, and uncertainty around evolving CAC rules.
Business risks include a limited operating history, net losses, going concern and liquidity pressures, heavy dependence on a few major customers, supplier and quality-control risks, rising raw material and labor costs, and seasonality. The report also discloses material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of independent directors and an audit committee.